Brief: Revance Provides An Update On Daxxify Commercial Launch

Revance Therapeutics

09/01/2023 13:30

Jan 9 (Reuters) - Revance Therapeutics Inc  RVNC.O :
    * REVANCE PROVIDES AN UPDATE ON DAXXIFY® COMMERCIAL LAUNCH
AND
PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
    * REVANCE THERAPEUTICS INC - PRELIMINARY UNAUDITED Q4
DAXXIFY®
REVENUE FROM PREVU OF BETWEEN $10.5 MILLION AND $11.5 MILLION
    * REVANCE THERAPEUTICS INC - PRELIMINARY UNAUDITED Q4 RHA
COLLECTION REVENUE OF BETWEEN $34.0 MILLION AND $35.0 MILLION, A
YOY INCREASE OF APPROXIMATELY 45%
    * REVANCE THERAPEUTICS - PRELIMINARY UNAUDITED CASH, CASH
EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DECEMBER 31, 2022
WERE APPROXIMATELY $340.0 MILLION
    * REVANCE THERAPEUTICS INC - DAXXIFY'S FULL-SCALE COMMERCIAL
LAUNCH EXPECTED TO BEGIN IN LATE Q1/EARLY Q2 OF 2023

Source text for Eikon:  ID:nBw2G9MhWa 
Further company coverage:  RVNC.O 
 ((reuters.briefs@thomsonreuters.com;))